Raymond James Cuts Knight Therapeutics (TSE:GUD) Price Target to C$7.50

Knight Therapeutics (TSE:GUD) had its price target cut by Raymond James from C$8.00 to C$7.50 in a report released on Thursday,BayStreet.CA reports. Raymond James also issued estimates for Knight Therapeutics’ Q4 2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.00 EPS and Q3 2025 earnings at $0.00 EPS.

A number of other equities analysts have also recently commented on GUD. Stifel Nicolaus raised shares of Knight Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the stock from C$5.75 to C$6.75 in a research note on Tuesday, August 13th. Stifel Canada raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th.

Knight Therapeutics Price Performance

GUD stock opened at C$5.19 on Thursday. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. Knight Therapeutics has a one year low of C$5.07 and a one year high of C$6.23. The stock has a market cap of C$525.28 million, a PE ratio of -25.95, a P/E/G ratio of -1,013.50 and a beta of 0.50. The firm has a 50 day simple moving average of C$5.71 and a two-hundred day simple moving average of C$5.73.

Insider Transactions at Knight Therapeutics

In related news, Senior Officer Amal Khouri sold 5,000 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of C$5.78, for a total transaction of C$28,919.00. Also, insider Sime Armoyan sold 300,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. Company insiders own 45.62% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.